HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

 
 
Thread Tools Display Modes
Prev Previous Post   Next Post Next
Old 11-16-2014, 09:42 AM   #1
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Post Coming treatments: Pfizer's Palbociclib

Although this is in trials for Er+ Her2- it is one to watch for breast cancer.

Palbociclib (PD-0332991)

Target: Inhibitor of cyclin-dependent kinases (CDK) 4 and 6
Disease focus: Metastatic breast cancer
Developer: Pfizer ($PFE)

Palbociclib has shown powerful effects in women with a common molecular form of metastatic breast cancer, prompting industry watchers to pump up the market potential of the oral agent. Pfizer CEO Ian Read has trumpeted the inhibitor of CDK 4 and 6 as a leading late-stage contender in the drug giant's resurgent R&D pipeline, and the FDA designated the compound as a "Breakthrough Therapy" with all the speedy development and review benefits of the status in April.

Breast cancer is the leading cause of cancer death in women. A variety of molecular drivers make breast cancer a heterogeneous disease, yet Pfizer investigators have found impressive evidence of efficacy for palbociclib in postmenopausal women with an ER-positive, HER2-negative form of the cancer. This molecular makeup represents 60% of postmenopausal cases of aggressive or metastatic breast cancer, making it the largest subgroup in this diverse population of cancer patients.

In December investigators impressed analysts with interim Phase II data that showed how breast cancer patients on palbociclib and Novartis' ($NVS) standard antihormone therapy Femara went more than 18 months longer without their disease worsening compared with patients on Femara alone. Based on the signs of efficacy against the major illness, Citigroup's Andrew Baum estimated potential annual sales of $5 billion. Yet industry watchers await full data from the study and evidence of improved overall survival, the true mark of a breakthrough.

With palbociclib, Pfizer is forging ahead in an area of oncology drug development with few successes. The drug targets two triggers in the tumor cell cycle to stymie development of cancer cells before DNA replication and cell division. Eli Lilly ($LLY) has a CDK 4/6 inhibitor of its own called LY2835219 in early stage development for advanced tumors and a Phase II study in patients with mantle cell lymphoma.

Pfizer has engineered a wide-ranging development program to study palbociclib for patients with a variety of cancers, some of which include ovarian cancer, multiple myeloma and acute lymphoblastic leukemia.

For more:
FDA stokes blockbuster hopes with 'breakthrough' brand for Pfizer cancer drug
Pfizer seeks inside track at FDA for blockbuster breast-cancer hopeful
Pfizer eyes PhIII with impressive data for breast-cancer fighter
__________________
Diagnosed 2007
Stage IIb Invasive Ductal Carcinoma, Pagets, 3 of 15 positive nodes

Traditional Treatment: Mastectomy and Axillary Node Dissection followed by Taxotere, 6 treatments and 1 year of Herceptin, no radiation
Former Chemo Ninja "Takizi Zukuchiri"

Additional treatments:
GP2 vaccine, San Antonio Med Ctr
Prescriptive Exercise for Cancer Patients
ENERGY Study, UCSD La Jolla

Reconstruction: TRAM flap, partial loss, Revision

The content of my posts are meant for informational purposes only. The medical information is intended for general information only and should not be used in any way to diagnose, treat, cure, or prevent disease
'lizbeth is offline   Reply With Quote
 

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 09:14 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter